PDS Biotechnology PDSB January 2022 Investor Presentation

Clinical-stage immunotherapy company developing Versamune and Infectimune platforms to treat cancer and infectious disease by priming antigen-specific killer T-cells. Three Phase 2 oncology trials underway with partnerships including Merck and MD Anderson Cancer Center. Debt-free with $69.7M cash as of September 2021.